List view / Grid view
We had the privilege of speaking to Dr Mark R. Kelley, Associate Director of Basic Science at the Indiana University Melvin and Bren Simon Comprehensive Cancer Center, and Betty and Earl Herr Professor in Pediatric Oncology Research, prior to his talk at PharmSci 360 in 2024. He elucidates what makes…
Proactive approaches to labelling and artwork in preclinical stages of drug development reduce delays, minimise risk and expedite time to market.
Tune in to this episode where we explore how innovative assays and human-relevant cell models are transforming toxicity screening in drug development.
Organoids with SMA-pathology uncovered key findings about the disease, which could be utilised to develop new therapeutic options.
Researchers discovered two potential new drug applications with the possible clinical use of surfactant early in COVID-19 cases.
The new agent, DIF-1(+3), proved to be as effective against drug-resistant malaria as it was against susceptible strains.
Discover how Cue Biopharma harnesses the curative potential of the body’s intrinsic immune system to develop treatments for oncology and autoimmune diseases. Here, Anish Suri, Chief Scientific Officer of Cue Biopharma, explains how its platforms and biologics are designed to selectively modulate disease-specific T cells to restore immune balance, aiming…
Blocking the TGF-β signalling pathway produced effective antitumour activity against hepatocellular carcinoma.
In this exclusive interview with Elicio Therapeutics, we explore the transformative potential of liquid biopsy in oncology drug development, particularly spotlighting its application in Elicio’s AMPLIFY-201 study of ELI-002, a promising therapeutic cancer vaccine candidate.
Researchers have created a new T cell atlas which could aid the development of novel drug therapies for immune-mediated diseases.
20 June 2024 | By Eurofins DiscoverX
Join this webinar to discover how GPCR functional, cell-based assays determine off-target effects, reveal safety issues, and define drug mechanism of action to ultimately evaluate the therapeutic potential of candidate molecules.
The novel drug, ETD001, could provide an improved approach for mucus clearance in cystic fibrosis patients.
In this Q&A, Associate Director, Research at Immunocore, Dr Ana Pereira Ribeiro, talks about IMC-R117C, a T cell receptor bispecific immunotherapy directed towards a novel target, PIWIL1, and about to enter Phase I testing in colorectal and gastrointestinal cancers.
The future of liquid biopsy is poised to revolutionise medical diagnostics and treatment. Explore the latest advancements and future prospects of liquid biopsy in our comprehensive eBook.
As antimicrobial resistance continues to advance, novel therapeutics are needed that stop infection and do not contribute to resistance. Australian biotech Recce Pharmaceuticals is paving the way for a new class of synthetic anti-infectives and providing hope for those with resistant infections. Recce’s lead candidate, RECCE® 327 (R327), is a…
